Dr. Ho Ling Yin - Rheumatology
Specialist in Rheumatology
Highlights
- MCHK RegisteredVerified
- Specialist in RheumatologyBachelor of Medicine and Bachelor of Surgery (MBChB) · Hong Kong College of Physicians · Medical degree 2002
- InsuranceBeing compiled｜See details
About
Dr. Ho Ling Yin is a registered Rheumatology specialist in Hong Kong.
Education
Specialist in Rheumatology
- Bachelor of Medicine and Bachelor of Surgery (MBChB)Bachelor of Medicine and Bachelor of Surgery (MBChB)2002
Hong Kong Academy of Medicine fellowships
- FHKCPFellow, Hong Kong College of Physicians
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Ho Ling Yin? Claim page and update insurance →
FAQ
Is Dr. Ho Ling Yin any good?
Dr. Ho Ling Yin is a registered Rheumatology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Ho Ling Yin do?
Dr. Ho Ling Yin practises in Rheumatology.
Are you Dr. Ho Ling Yin? Claim this page to update and manage.
ClaimResearch and publications
16 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Tixagevimab-cilgavimab for the prevention of COVID-19: real-world experience in patients with rheumatic diseases receiving rituximab.Clinical and experimental rheumatology · 2025
- Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.Clinical rheumatology · 2023
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus Erythematosus.Inflammation · 2023
- Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study.Therapeutic advances in musculoskeletal disease · 2022
- Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients.Therapeutic advances in musculoskeletal disease · 2022
- Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.Bone · 2021
- Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.Annals of the rheumatic diseases · 2020
- Trend of Survival of a Cohort of Chinese Patients With Systemic Lupus Erythematosus Over 25 Years.Frontiers in medicine · 2020
- Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies.Lupus · 2020
- Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.Annals of the rheumatic diseases · 2019
- Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis.Arthritis research & therapy · 2018
- Effect of the metabolic syndrome on organ damage and mortality in patients with systemic lupus erythematosus: a longitudinal analysis.Clinical and experimental rheumatology · 2018
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer